Skip to main content
Premium Trial:

Request an Annual Quote

IHT Begins Selling Opko's Protein Biomarker Prostate Cancer Dx

Premium

Opko Health said this week that its partner International Heath Technology has begun selling its Opko 4kscore prostate cancer test in Europe as part of IHT's ProstateCheck program.

The 4kscore diagnostic uses two protein biomarkers in the kallikrein family along with prostate-specific antigen for early detection of prostate cancer. Opko licensed the two markers from Finnish biotech firm Artic Partners in January (PM 1/30/2012).

The biomarkers were identified by researchers at Sweden's University of Malmo, Finland's University of Turku, and New York's Memorial Sloan Kettering Cancer Center, who showed that the markers, in combination with prostate specific antigen, could predict initial biopsy results in men suspected of having prostate cancer.

The researchers tested the markers in more than 8,000 men, and the markers were independently validated in the European Randomized Study of Prostate Cancer Screening.

According to Opko, use of the panel could potentially eliminate more than 50 percent of unnecessary prostate biopsies by improving on the specificity of existing PSA tests.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.